How can α-synuclein aggregation be prevented to slow progression of PD?

Our correspondent’s highlights from the symposium are meant as a fair representation of the scientific content presented. The views and opinions expressed on this page do not necessarily reflect those of Lundbeck.

  1. Hung AY, Schwartzchild MA. Neurotherapeutics. 2014;11:34–46.
  2. Hawkes CH, et al. Parkinsonism Relat Disord. 2010;16:79–84.
  3. Poewe W, et al. Neuropharmacol. 2020;171:108085.
  4. Goedert M, et al. Nat Rev Neurol. 2013;9:13–24.
  5. Braak H, et al. Neurobiol Aging. 2003;24:197–211.
  6. Angot E, et al. Lancet Neurol. 2010;9:1128–38.
  7. Polymeropoulos MH, et al. Science. 1997;276:2045–7.
  8. Wakabayashi K. Neuropathology. 2020;
  9. McFarthing K, et al. J Parkinsons Dis. 2020;10:757–74.
Du lämnar Progress in Mind Sverige
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
Den här informationen är endast avsedd för hälso- och sjukvårdspersonal
Register for access to Progress in Mind in your country